Literature DB >> 9344919

Failure to complement infectivity of EBV and HSV-1 glycoprotein B (gB) deletion mutants with gBs from different human herpesvirus subfamilies.

S K Lee1, T Compton, R Longnecker.   

Abstract

Glycoprotein B (gB) is conserved among the herpesvirus family which infects a broad range of species. To investigate the functional homology of human alpha-herpesviruses, beta-herpesviruses, and gamma-herpesviruses gB proteins, complementation studies were performed with gB genes from each subfamily member using EBV gp110 (EBV gB homologue) and HSV-1 gB null mutants. Neither the alpha-herpesvirus HSV-1 gB gene nor the beta-herpesvirus HCMV gB gene were able to complement the gp110 null mutant. Conversely, neither the beta-herpesvirus HCMV gB or the gamma-herpesvirus EBV gp110 gene were able to complement HSV-1 gB null mutants. To further investigate functional domains of EBV gp110 and HSV-1 gB, gB-gp110 chimeric proteins were constructed. Surprisingly, none of the chimeric proteins were able to complement either HSV-1 gB null mutants or EBV gp110 null mutants. These results demonstrate that there is not sufficient functional homology between the different gBs to allow complementation in other subfamily members of the herpesvirus family. Copyright 1997 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9344919     DOI: 10.1006/viro.1997.8765

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  12 in total

1.  Cleavage of Epstein-Barr virus glycoprotein B is required for full function in cell-cell fusion with both epithelial and B cells.

Authors:  Jessica Sorem; Richard Longnecker
Journal:  J Gen Virol       Date:  2009-03       Impact factor: 3.891

2.  Primary B-cell infection with a deltaBALF4 Epstein-Barr virus comes to a halt in the endosomal compartment yet still elicits a potent CD4-positive cytotoxic T-cell response.

Authors:  Bernhard Neuhierl; Regina Feederle; Dinesh Adhikary; Birgit Hub; Karsten Geletneky; Josef Mautner; Henri-Jacques Delecluse
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

3.  Role of the varicella-zoster virus gB cytoplasmic domain in gB transport and viral egress.

Authors:  Thomas C Heineman; Susan L Hall
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Receptor-binding properties of a soluble form of human cytomegalovirus glycoprotein B.

Authors:  K A Boyle; T Compton
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

5.  Cytoplasmic domain signal sequences that mediate transport of varicella-zoster virus gB from the endoplasmic reticulum to the Golgi.

Authors:  T C Heineman; N Krudwig; S L Hall
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

6.  Proteolytic processing of human cytomegalovirus glycoprotein B is dispensable for viral growth in culture.

Authors:  Tanja Strive; Eva Borst; Martin Messerle; Klaus Radsak
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

7.  Mutational analyses of Epstein-Barr virus glycoprotein 42 reveal functional domains not involved in receptor binding but required for membrane fusion.

Authors:  Amanda L Silva; Jasmina Omerovic; Theodore S Jardetzky; Richard Longnecker
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  Hydrophobic residues that form putative fusion loops of Epstein-Barr virus glycoprotein B are critical for fusion activity.

Authors:  Marija Backovic; Theodore S Jardetzky; Richard Longnecker
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

9.  Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood.

Authors:  Uk Yeol Moon; Su Jin Park; Sang Taek Oh; Wan-Uk Kim; Sung-Hwan Park; Sang-Heon Lee; Chul-Soo Cho; Ho-Youn Kim; Won-Keun Lee; Suk Kyeong Lee
Journal:  Arthritis Res Ther       Date:  2004-05-07       Impact factor: 5.156

10.  Bovine herpesvirus 4 glycoprotein B is indispensable for lytic replication and irreplaceable by VSVg.

Authors:  Valentina Franceschi; Antonio Capocefalo; Sandro Cavirani; Gaetano Donofrio
Journal:  BMC Vet Res       Date:  2013-01-09       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.